At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 348 enrolled
Drug / intervention
CT-P42 +1 morebiological
Likely dose
CT-P42 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
In Brief
A Phase 3 clinical trial evaluating CT-P42 and Eylea for Diabetic Macular Edema (DME). Completed, enrolled 348 participants across 1 site.
Detailed Summary
This is a Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in comparison with Eylea in Patients with Diabetic Macular Edema
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema (DME)
CountriesSlovakia
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartJul 2021
Primary CompletionOct 2022
Study CompletionApr 2023
TodayJul 2026
First PostedFeb 4, 2021
Enrollment StartJul 22, 2021
Primary CompletionOct 14, 2022
Study CompletionApr 24, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.4 years ago
Interventions
CT-P42biological
2mg/0.05 mL by Intravitreal injection
Eyleabiological
2mg/0.05 mL by Intravitreal injection